Clinicopathological characteristics and outcomes of colorectal mucinous adenocarcinoma: a retrospective analysis from China.

"Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer XW declared a shared affiliation with the authors AH, ZS, HH, JG to the handling editor at the time of review."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was funded by the Capital’s Funds for Health Improvement and Research (CFH 2020-1-6041) and the National Natural Science Foundation (82073223)."

"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Peking University Shougang Hospital Medical Ethics Committee (protocol code IRBK-2022-028-01) on June 8th, 2022. And the study was registered on the official website of China Clinical Trial Registration Center (ChiCTR2300076785). The authors thank Dandan Huang Ph.D., Jingxuan Xu Ph.D., and Yu Cheng MSc. for collecting data. We collected clinicopathological information on patients who underwent CRC surgery at Peking University Shougang Hospital between January 2016 and December 2019. We defined NMAC as an adenocarcinoma in which extracellular mucus accounted for less than 5% of the tumor volume. Inclusion criteria included patients diagnosed with CRC between January 2016 and December 2019 at Peking University Shougang Hospital and the pathological diagnosis of the surgical specimen was adenocarcinoma. Exclusion criteria were: pathological types of CRC other than NMAC, ACWM (extracellular mucus accounting for more than 5% and less than 50% of tumor volume), and MAC (extracellular mucus accounting for 50% or more of tumor volume) (); multiple primary cancers; history of malignancy; familial adenomatous polyposis. We registered on the official website of China Clinical Trial Registration Center (ChiCTR2300076785)."